Equity Profile

TXG

10x Genomics, Inc.

Health CareLife Sciences Tools & Services$5.3B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

10x Genomics, Inc. (TXG) operates in the health care sector, focusing on life sciences tools and services....

Key Metrics to Watch

Revenue Growth

Investors will be looking for signs of demand for 10x Genomics' products, especially in a competitive landscape.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TXG Q2-2026 Earnings Preview

Context

Company Snapshot

10x Genomics, Inc. (TXG) operates in the health care sector, focusing on life sciences tools and services. The company develops innovative technologies for genomic analysis, which are crucial for advancing research in biology and medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+43.83%

Avg Stock Reaction

+0.03%

Last Quarter Recap

In Q1-2026, 10x Genomics reported an EPS of -$0.10, beating estimates by 66%. Despite the positive surprise, the stock declined slightly the following day.

Management Promises & Guidance

Focus on expanding product offerings.
Enhance customer engagement and support.
Invest in research and development for new technologies.

Expectations

Wall Street Expectations

Overall expectations for 10x Genomics are mixed, with some analysts optimistic about growth while others remain cautious due to market competition.

Bull Case

The company could see strong revenue growth driven by new product launches and increased adoption of its technologies in research institutions.

Bear Case

Challenges in maintaining market share against competitors could lead to disappointing revenue and earnings results.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the revenue growth rate compared to last year?

Revenue growth is critical for assessing the company's ability to expand its market presence and meet investor expectations.

How does management plan to address competitive pressures in the market?

Understanding the company's strategy to maintain its competitive edge will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for 10x Genomics to capture market share through innovative product offerings, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

The company's recent product launches have received positive feedback from key customers.

Options pricing suggests a higher volatility expectation than historical averages, indicating potential for significant movement.

The strong EPS surprise in the last quarter indicates underlying strength that may not be fully appreciated.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious outlook from analysts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to grow revenue and navigate competitive challenges.

Bull Confirmed If

Revenue growth of 15% or better compared to the same quarter last year would confirm the bull case.

Bear Confirmed If

A decline in revenue or failure to address competitive pressures would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±30.9%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±30.9% while TXG has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

69.6%

Calls (444K)P/C Ratio: 0.03Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If 10x Genomics beats expectations, history suggests a potential stock increase of around 3.1%, confirming positive market sentiment.

In-Line / Cautious

An in-line result may lead to a muted response, as management's commentary could drive uncertainty.

Miss

If the company misses expectations, history suggests a potential decline of around 1.5%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Management's commentary on competitive landscape and strategies.
3Details on customer engagement and retention efforts.
4Any guidance on future revenue expectations.
5Insights into research and development initiatives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

10x Genomics, Inc. (TXG) operates in the health care sector, focusing on life sciences tools and services....

Key Metrics to Watch

Revenue Growth

Investors will be looking for signs of demand for 10x Genomics' products, especially in a competitive landscape.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TXG Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+43.83%

Avg Stock Reaction

+0.03%

Last Quarter Recap

In Q1-2026, 10x Genomics reported an EPS of -$0.10, beating estimates by 66%. Despite the positive surprise, the stock declined slightly the following day.

Management Promises & Guidance

Focus on expanding product offerings.
Enhance customer engagement and support.
Invest in research and development for new technologies.

Expectations

Wall Street Expectations

Overall expectations for 10x Genomics are mixed, with some analysts optimistic about growth while others remain cautious due to market competition.

Bull Case

The company could see strong revenue growth driven by new product launches and increased adoption of its technologies in research institutions.

Bear Case

Challenges in maintaining market share against competitors could lead to disappointing revenue and earnings results.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the revenue growth rate compared to last year?

Revenue growth is critical for assessing the company's ability to expand its market presence and meet investor expectations.

How does management plan to address competitive pressures in the market?

Understanding the company's strategy to maintain its competitive edge will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for 10x Genomics to capture market share through innovative product offerings, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

The company's recent product launches have received positive feedback from key customers.

Options pricing suggests a higher volatility expectation than historical averages, indicating potential for significant movement.

The strong EPS surprise in the last quarter indicates underlying strength that may not be fully appreciated.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious outlook from analysts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to grow revenue and navigate competitive challenges.

Bull Confirmed If

Revenue growth of 15% or better compared to the same quarter last year would confirm the bull case.

Bear Confirmed If

A decline in revenue or failure to address competitive pressures would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±30.9%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±30.9% while TXG has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

69.6%

Calls (444K)P/C Ratio: 0.03Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If 10x Genomics beats expectations, history suggests a potential stock increase of around 3.1%, confirming positive market sentiment.

In-Line / Cautious

An in-line result may lead to a muted response, as management's commentary could drive uncertainty.

Miss

If the company misses expectations, history suggests a potential decline of around 1.5%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Management's commentary on competitive landscape and strategies.
3Details on customer engagement and retention efforts.
4Any guidance on future revenue expectations.
5Insights into research and development initiatives.